Although it was reported that the HO-1-mediated migration/invasion may be ascribed to intramembrane proteolysis and nuclear translocation, which are independent of its enzymatic activity [29], our results suggest that the HO-1 activity or the products of heme degradation can be pharmacologically targeted to suppress cell motility in thyroid cancer. Here, HMOX1 is linked to thyroid gland carcinoma.